1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Indegene Limited

Indegene Limited

571.90
INR
-16.20
(-2.75%)
17.19EPS
30.35P/E
126.37BMarket Cap
Oct 29Next Earn
Indegene Limited
NSE:INDGN
(National Stock Exchange of India)

Recent

price

571.90

P/E

ratio

30.35

div

yld

- -

ROIC.AI

2021
2022
2023
2024
2025
2026
TTM
INR
40.38
69.57
96.38
108.4
119.75
146.33
157.14
Revenue per Share
6.24
6.89
11.12
14.09
17.15
16.72
17.31
Basic EPS, GAAP
6.33
11.38
4.66
20.8
17.37
25.28
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
2
- -
Dividend per Share
13.58
31.98
44.53
59.82
108.98
130.49
- -
Book Value per Share
11.93
29.55
22.82
37.58
86.37
63.24
- -
Tangible Book Value per Share
239
239
239
239
237
240
240
Basic Weighted Avg Shares
9,663
16,646
23,061
25,896
28,393
35,105
37,694
Sales/Revenue/Turnover
22.69
15.26
14.58
16.79
15.99
14.18
13.41
Operating Margin (%)
346
335
598
761
802
1,265
1,471
Depreciation Expense
1,494
1,648
2,661
3,367
4,067
4,011
4,152
Net Income, GAAP
19.78
28.11
26.69
26.58
24.59
23.6
23.76
Effective Tax Rate (%)
15.46
9.9
11.54
13
14.32
11.43
11.02
Profit Margin (%)
2,599
6,896
9,596
11,799
19,655
15,322
- -
Working Capital
311
439
4,795
3,986
724
1,050
- -
LT Debt
3,331
7,639
10,637
14,291
26,156
31,387
- -
Total Equity
- -
24.1
20.38
18.59
15.23
12.05
- -
Return on Invested Capital (%)
- -
28.01
24.13
21.27
18.18
13.78
- -
Return on Capital (%)
- -
30.28
29.12
27.01
20.11
13.94
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
394
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
1,050
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
240
241
241
Market Capitalization
124,908
104,534
126,374

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
26,184
- -
Cash, Cash Equivalents & STI
- -
14,814
- -
Accounts Receivable, Net
- -
7,702
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
10,862
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
394
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
61.19%
20%
Free Cash Flow
- -
79.4%
47.22%
Net Income, GAAP
- -
23.55%
-1.38%
Sales/Revenue/Turnover
- -
31.28%
23.64%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
6,765
6,868
7,204
7,556
28,393
2026
7,608
- -
9,421
10,034
35,105
2027
10,631
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
3.79
3.84
4.59
4.91
17.15
2026
4.86
- -
4.29
3.32
16.72
2027
4.84
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
2
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Indegene Limited (INDGN.NS) is a digital-first life sciences commercialization company that provides technology-enabled solutions to biopharmaceutical, emerging biotech, and medical device companies across the product lifecycle. The company offers enterprise medical solutions, including regulatory affairs, pharmacovigilance, medical writing, clinical development, and real-world evidence; enterprise commercial solutions, such as market access, pricing strategy, sales force effectiveness, and health economics outcomes research; and omnichannel activation services encompassing digital marketing, AI-driven social intelligence, multichannel engagement, and analytics platforms like the Indegene Digital Command Center and NEXT technology platforms. Founded in 1998 and headquartered in Bengaluru, India, with key operational centers in Princeton, New Jersey, and offices across the United States, Europe, Asia-Pacific, and other regions, Indegene serves leading global clients including 20 of the top 20 biopharma companies. Recent developments include its initial public offering in May 2024 raising approximately $220 million; the acquisition of BioPharm Communications, a US-based AI-driven marketing agency, for up to $106 million in October 2025 to bolster AdTech and digital advertising capabilities; the planned acquisition of Cake Group, a DACH region healthcare marketing agency, for up to EUR 8.5 million via its Ireland subsidiary, expected to close in January 2026; expansion into Europe with a new entity in Spain in February 2025 and a London center launch in March 2025; and a strategic partnership with Microsoft announced in July 2024.